PetMed Express Reports 17.2% Revenue Decline and Organizational Changes for Fiscal Year Ending March 31, 2025

PetMed Express, Inc. has reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with total revenues of approximately $227 million, a decrease of 17.2% from $274.1 million in the previous fiscal year. The company attributed this decline to a strategic reduction in advertising, broader macroeconomic factors, and increased consumer promotional usage. The net loss for the year was approximately $6.3 million, a slight improvement from a loss of $7.5 million in fiscal 2024. The average order value increased marginally to $97 from $94, and the company acquired approximately 351,000 new customers during the year, down from 457,000 in the prior year.

In addition to the financial downturn, PetMed Express has undergone significant organizational changes, including the acquisition of PetCareRx in April 2023 for approximately $36 million. This acquisition expanded the company's product offerings beyond pet prescriptions to include a wider range of pet foods and supplies. However, the company has faced challenges in integrating these operations, as evidenced by the ongoing issues with its internal controls and the need for a restatement of financial results for previous fiscal years due to misclassifications in revenue and expenses.

Operationally, the company reported a decrease in reorder sales, which fell by 15.5% to approximately $188 million, primarily due to a decline in prescription medication sales. The cost of sales also decreased by 16.6% to $157.8 million, reflecting the overall drop in sales. The gross profit margin slightly decreased to 30.5% from 30.9% in the previous year. The company has also identified material weaknesses in its internal controls over financial reporting, particularly in its revenue recognition processes and vendor reimbursements, which have led to an adverse opinion from its independent auditors regarding the effectiveness of its internal controls.

Looking ahead, PetMed Express has outlined a series of strategic initiatives aimed at improving customer experience and operational efficiency. The company plans to enhance its technology infrastructure and expand its omnichannel presence, including launching private label products on platforms like Amazon. However, the company acknowledges that future sales may be adversely affected by increased competition and changing consumer behaviors post-pandemic. The management remains cautious about the outlook, emphasizing the need for continued monitoring of market conditions and consumer spending patterns.